Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar

Executive Summary

Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist
Advertisement

Related Content

Bristol Outsourcing Of Cefzil, Tequin To Ventiv May Be New Model For CSOs
Merck To Sign 50 Business Development Deals In 2005
Bristol submits muraglitazar, abatacept to FDA
Merck To Increase Internal R&D But Reduce Outside Deals In 2005
AstraZeneca Galida NDA Delayed Until 2007 Due To PPAR Safety Concerns
Merck Sees Slightly More Success With External Rx Than Internal Candidates
Bristol Is Not Bayer: Primary Care Strategy Is “Different, Not Exit”
Primary Care Rx Market Offers Second-Rate Return On Investment – Bristol
Merck discontinues Phase III diabetes drug
Merck/Kyorin Phase III Dual PPAR Agonist On First-In-Class Path For Diabetes
Advertisement
UsernamePublicRestriction

Register

PS043877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel